| Literature DB >> 23866063 |
Vyry Na Wouatsa1, Laxminarain Misra2, Shiv Kumar3, Om Prakash3, Feroz Khan3, Francois Tchoumbougnang4, R Kumar Venkatesh5.
Abstract
BACKGROUND: Zanthoxylum zanthoxyloides and Z. leprieurii fruits are commonly used in traditional system of medicine for diarrhea, pain, wound healing, etc. in Cameroon, Africa. Z. leprieurii fruits have been chemically studied for its bioactive compounds whereas the investigation on Z. zanthoxyloides fruits is lacking.Entities:
Keywords: Antibacterial; Cytotoxic activities; Molecular modeling; QSAR studies; Rutaceae; Structure elucidation; Z. leprieurii; Zanthacridones; Zanthoxylum zanthoxyloides
Year: 2013 PMID: 23866063 PMCID: PMC3750308 DOI: 10.1186/1752-153X-7-125
Source DB: PubMed Journal: Chem Cent J ISSN: 1752-153X Impact factor: 4.215
Figure 1Structures of acridones 1- 10.
H NMR spectral data for 1-3, 8-10 (300 MHz, in CDCl, δ in ppm)
| 2 | 7.01(d,3.0) | 6.58(d,3.0) | 6.12(s) | - | - | - |
| 4 | 7.55(d,3.0) | 6.44(d,3.0) | - | - | - | - |
| 5 | - | 7.39(d,3.0) | - | 7.40(dd,8.0,3.0) | 7.41(dd,8.0,3.0) | 7.34(dd,8.0,3.0) |
| 6 | - | - | 7.20(d,3.0) | 7.61(ddd,8.0,8.0,3.0) | 7.59(ddd,8.0,8.0,3.0) | 7.55(ddd,8.0,8.0,3.0) |
| 7 | 7.21(d,8.0) | 7.07(dd,8.0,3.0) | - | 7.29(ddd,8.0,8.0,3.0) | 7.34(ddd,8.0,8.0,3.0) | 7.34(ddd,8.0,8.0,3.0) |
| 8 | 7.99(d,8.0) | 7.89(d,8.0) | 7.82(d,3.0) | 7.82(dd,8.0,3.0) | 8.40(dd, 8.0, 3.0) | 8.39(dd,8.0,3.0) |
| 1-OMe | 4.40(s) | - | 4.44(s) | - | - | - |
| 3-OMe | - | 3.93(s) | - | - | - | - |
| 4-OMe | - | - | - | 3.98(s) | - | - |
| 5-OMe | 4.10(s) | - | - | - | - | - |
| 6-OMe | 4.01(s) | - | - | - | - | - |
| N-Me | - | - | 3.90(s) | 3.77(s) | 3.69(s) | 3.70(s) |
| 2’-Me | - | - | - | 1.30(s) | 1.33(s) | 1.32(s) |
| 1.30(s) | 1.42(s) | 1.28(s) | ||||
| 3’ | - | - | - | 2.72(dd,13,10) | 2.68(dd,13,3.5) | 3.23(overlapping m) |
| 3.07(dd,13,3.5) | 3.00(dd,13,3.5) | 3.25(overlapping m) | ||||
| 4’ | - | - | - | 3.50(dd,10,3.5) | 3.63(dd,10,3.5) | 4.85(dd,10.0,10.0) |
| 1-OH | - | 12.12 | - | 15.05 | 15.00 | 14.92 |
| 3-OH | 9.02 | - | 9.05* | - | - | - |
| 4-OH | - | - | 9.00* | - | 9.05 | 9.10 |
| 5-OH | - | - | 9.32* | - | - | - |
| 6-OH | - | 8.90 | - | - | - | - |
| 7-OH | - | - | 8.92* | - | - | - |
*Assignments interchangeable.
C NMR spectral data for 1-3, 8-10 (75 MHz, in CDCl, δ in ppm)
| 1 | 158.0 (s) | 161.2 (s) | 160.0 (s) | 162.1 (s) | 160.0 (s) | 159.3(s) |
| 2 | 113.5 (d) | 94.3 (d) | 92.7 (d) | 118.2 (s) | 117.5 (s) | 160.2 (s) |
| 3 | 152.6 (s) | 162.4 (s) | 161.3 (s) | 166.5 (s) | 166.4 (s) | 166.5 (s) |
| 4 | 104.8 (d) | 90.7 (d) | 130.2 (s) | 123.0 (s) | 122.1 (s) | 131.2 (s) |
| 4a | 143.3 (s) | 140.7 (s) | 141.2 (s) | 139.3 (s) | 139.0 (s) | 124.8 (s) |
| 5a | 144.0 (s) | 140.7 (s) | 141.3 (s) | 139.3 (s) | 140.2 (s) | 133.2 (s) |
| 5 | 145.1 (s) | 104.4 (d) | 146.2 (s) | 115.0 (d) | 116.1 (d) | 114.5 (d) |
| 6 | 143.3 (s) | 144.0 (s) | 119.8 (d) | 131.2 (d) | 131.3 (d) | 131.4 (d) |
| 7 | 118.3 (d) | 117.2 (d) | 143.1 (s) | 123.0 (d) | 123.0 (d) | 123.6 (d) |
| 8 | 162.3 (d) | 126.9 (d) | 117.2 (d) | 124.0 (d) | 124.1 (d) | 126.8 (d) |
| 8a | 115.6 (s) | 120.4 (s) | 121.5 (s) | 121.5 (s) | 121.6 (s) | 122.1 (s) |
| 9 | 178.2 (s) | 180.8 (s) | 181.1 (s) | 177.2 (s) | 178.3 (s) | 181.6 (s) |
| 9a | 104.7 (s) | 108.2 (s) | 108.1 (s) | 114.9 (s) | 114.9 (s) | 116.2 (s) |
| OMe | 57.5 (q) | 56.4 (q) | 60.9 (q) | 62.8 (q) | - | - |
| 59.3 (q) | - | - | - | - | - | |
| 61.9 (q) | - | - | - | - | - | |
| N-Me | - | - | 34.3 (q) | 30.5 (q) | 31.5 (q) | 31.7 (q) |
| 2’ | - | - | - | 73.4 (s) | 73.4 (s) | 72.3 (s) |
| 2’Me | - | - | - | 24.4 (q) | 25.0 (q) | 24.7 (q) |
| 26.1 (q) | 26.2 (q) | 26.0 (q) | ||||
| 3’ | - | - | - | 28.1 (t) | 28.2 (t) | 28.1 (t) |
| 4’ | - | - | - | 79.6 (d) | 78.6 (d) | 92.3 (d) |
*The multiplicity of the signals obtained by DEPT 135.
antibacterial activity of extracts of , and acridone alkaloids
| | ||||
|---|---|---|---|---|
| >500 | >500 | 500 | >500 | |
| nt | 125 | 125 | nt | |
| 250 | 125 | >500 | 250 | |
| 250 | 500 | >500 | 500 | |
| nt | >500 | 250 | nt | |
| nt | >500 | 250 | nt | |
| Kanamycin | 0.53 | 4.16 | 62.5 | 6.94 |
| Extracts | | | | |
| >1000 | 250 | 1000 | >1000 | |
| >1000 | 500 | >1000 | >1000 | |
Gram-positive bacteria: BS = Bacillus subtilis MTCC121, ML = Micrococcus luteus MTCC2470 and SA = Staphylococcus aureus MTCC96, Gram-negative bacteria: PA = Pseudomonas aeruginosa MTCC741, nt = not tested. Kanamycin is the standard antibiotic.
Figure 2Molecular docking of active acridone alkaloids against (A) anticancer target protein aromatase in human (compounds 1, 8, 9 and 10) and (B) antibacterial WAAG protein of bacteria (compounds 1, 2, 3, 4, 9 and 10).
Results of molecular docking experiments targeting antibacterial protein WAAG
| 16 | ASP-19, ILE-285, GLY-284, LYS-209, ALA-283, GLU-281, ARG-261, GLY-15, ARG-208, ARG-18, ARG-173, GLU-289 | -10.7 | |
| Uridine-5’-diphosphate-2-deoxy-2-fluoro-alpha- d-glucose (Control inhibitor) | |||
| 03 | ARG-173, LYS-209, ARG-261 | -8.6 | |
| Compound 1 | |||
| 02 | ARG-173, GLY-289 | -8.5 | |
| Compound 2 | |||
| 06 | PHE-13, ALA-99, SER-204, GLY-284, ILE-285, | -7.6 | |
| Compound 3 | |||
| 01 | PHE-13 | -7.0 | |
| Compound 4 | |||
| 07 | ARG-208, VAL-286, GLY-281, ALA-283, GLY-284, ILE-285, | -8.6 | |
| Compound 9 | |||
| 03 | GLY-15, GLY-281, ILE-285 | -8.1 | |
| Compound 10 |
Derived pharmacophore model for antibacterial activity of acridones against
| 4.668387 | >4.1466 | significantly active | >500 | Non active | |
| 4.655514 | >4.1466 | significantly active | Not tested | Not tested | |
| 4.409138 | >4.1466 | significantly active | 125 | Active | |
| 5.006913 | >4.1466 | significantly active | 125 | Active | |
| 3.892896 | <4.1466 | Non-significant activity | Not tested | Not tested | |
| 4.049106 | <4.1466 | Non-significant activity | Not tested | Not tested | |
| 2.944231 | <4.1466 | Non-significant activity | 500 | Less active | |
| 4.008224 | <4.1466 | Non-significant activity | >500 | Non active | |
| 4.189883 | >4.1466 | significantly active | Not tested | Not tested | |
| 4.479721 | >4.1466 | significantly active | >500 | Not active |
The threshold score (S) of 4.1466 has been selected for the screening of lead compounds.
cytotoxicity of acridone 1, 4, 7 and 8
| | ||||
|---|---|---|---|---|
| 86 | >300 | 229 | 272 | |
| >300 | >300 | >300 | >300 | |
| >300 | >300 | >300 | >300 | |
| >300 | >300 | 205 | >300 | |
| Doxorubicin | 1.4 | 6.0 | 3.6 | 8.6 |
WRL-68 = Liver cancer cell lines, CaCO2 = colon cancer, MCF-7 = breast cancer, PC-3 = prostate cancer. Doxorubicin Sigma D-1515 is the standard used.
Results of molecular docking experiments targeting anticancer protein uinine reductase (PDB: 3G5M) and aromatase (PDB: 3EQM)
| 2 | ASP-309, MET-374 | -9.5 | |
| Androstenedione (control inhibitor) | |||
| 02 | PHE-17, THR-147 | -5.8 | |
| 6-methoxy-9-methyl[1,3]dioxolo[4,5-h]quinolin- 8(9 h)-one (Control inhibitor) | |||
| 04 | LEU-103, TYR-104, SER-107, GLY-149 | -6.1 | |
| Compound 1 | |||
| 04 | THR-148, TYR-155, SER-164 | -6.7 | |
| Compound 8 | |||
| 06 | PHE-106, THR-147, THR-148, TYR-155, SER-164 | -7.3 | |
| Compound 9 | |||
| 03 | LEU-103, PHE-106, THR-147 | -7.7 | |
| Compound 10 |
Derived pharmacophore model for anticancer activity of acridones active against human cancer cell line MCF-7
| 1. | 4.2712 | > 4.1274 | significantly active | 229 | Poor activity |
| 2. | 3.5826 | < 4.1274 | Non-significant activity | Not tested | Not tested |
| 3. | 3.6316 | < 4.1274 | Non-significant activity | Not tested | Not tested |
| 4. | 3.6796 | < 4.1274 | Non-significant activity | >300 | Non active |
| 5. | 3.3015 | < 4.1274 | Non-significant activity | >300 | Non active |
| 6. | 2.9402 | < 4.1274 | Non-significant activity | Not tested | Not tested |
| 7. | 2.4587 | < 4.1274 | Non-significant activity | Not tested | Not tested |
| 8. | 5.1457 | > 4.1274 | Significantly active | 205 | Poor activity |
| 9. | 4.9482 | > 4.1274 | Significantly active | Not tested | Not tested |
| 10. | 5.5092 | > 4.1274 | Significantly active | Not tested | Not tested |
The threshold score (S) of 4.1274 has been selected for the screening of lead compounds.
Compliance of acridone alkaloids with standard parameters of Lipinski’s rule of five for drug likeness and oral bioavailability
| 1.926 | 301.298 | 6 | 2 | 0 | |
| 1.862 | 257.245 | 5 | 3 | 0 | |
| 1.119 | 303.27 | 7 | 4 | 0 | |
| 2.189 | 285.299 | 5 | 1 | 0 | |
| 2.433 | 255.273 | 4 | 1 | 0 | |
| 1.913 | 271.272 | 5 | 2 | 0 | |
| 2.173 | 255.273 | 4 | 1 | 0 | |
| 2.476 | 355.39 | 6 | 2 | 0 | |
| 2.2 | 341.363 | 6 | 3 | 0 | |
| 2.411 | 357.362 | 7 | 3 | 0 |
miLogP = octanol/water partition coefficient, MW = molecular weight, nON = number of hydrogen acceptor, nOHNH = number of hydrogen donor, nviolations = violations from Lipinski’s rule.